EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease

Matthew P Stratton iD, Jessica L Centa, Vicki J Swier, Wanda L Pfeifer, Clarissa D Booth, Karlee Albert, John L Hunyara, Mitchell J Rechtzigel, Fox J Duelli, Hannah G Leppert, Frank Rigo iD, Trisha Smit und 4 weitere

Nucleic Acids Research · 2025

DOI: 10.1093/nar/gkaf1141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Matthew P Stratton und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Neuronal Ceroid-Lipofuscinoses, Retina, Molecular Chaperones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RFUMS, NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CLN3 Batten disease is a lethal pediatric neurodegenerative disease caused by mutations in the CLN3 gene. Typically, the disease manifests as vision loss in early childhood and progresses to neurological dysfunction and death in young adulthood. Most therapeutic developments have focused on treating the brain and may not protect against vision loss, which greatly affects quality of life. We have previously shown that a splice-switching antisense oligonucleotide (ASO) delivered to the central nervous system can reduce neurological disease burden in mouse models of CLN3 disease. Here, we apply a similar ASO approach for treating retinal dysfunction in a pig model of CLN3 Batten disease, which is more representative of human vision. A single intravitreal injection of ASO induces robust exon skipping in the retina for up to 12 months. The ASO treatment resulted in higher amplitudes on electroretinograms, suggesting mitigation of retinal dysfunction at early timepoints of disease. One ASO that efficiently induces exon skipping in vivo was well-tolerated and targets a region conserved in humans, making it a promising candidate for clinical translation. Our findings demonstrate the utility of an ASO-based approach to treat retinal dysfunction in CLN3 Batten disease and support broader ASO applications for treating ocular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseNeuronal Ceroid-LipofuscinosesRetinaMolecular ChaperonesMembrane GlycoproteinsAnimalsDisease Models, AnimalSwineHumansExonsElectroretinographyIntravitreal Injections

Substanzen

Oligonucleotides, AntisenseMolecular ChaperonesMembrane GlycoproteinsCLN3 protein, human

Autor:innen und Institutionen

  • Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.
  • School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.
  • Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, United States.
  • Pediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, United States.
  • Department of Ophthalmology and Visual Sciences, Institute for Vision Research, Carver College of Medicine, University of Iowa, IA City, IA 52242, United States.
  • Ionis Pharmaceuticals, Carlsbad, CA 92010, United States.

ORCID-Profile: Matthew P Stratton, Frank Rigo, Michelle L Hastings

Förderung

  • RFUMS
  • NIH HHS
  • NINDS NIH HHS
  • Batten Disease Support and Research Association
  • National Institutes of Health

Zitieren

APA

Stratton, M. P., Centa, J. L., Swier, V. J., Pfeifer, W. L., Booth, C. D., Albert, K., Hunyara, J. L., Rechtzigel, M. J., Duelli, F. J., Leppert, H. G., Rigo, F., Smit, T., Jafar-Nejad, P., Weimer, J. M., Drack, A. V., & Hastings, M. L. (2025). Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1141

Vancouver

Stratton MP, Centa JL, Swier VJ, Pfeifer WL, Booth CD, Albert K, et al. Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf1141

BibTeX
@article{Stratton2025,
  author = {Stratton, Matthew P and Centa, Jessica L and Swier, Vicki J and Pfeifer, Wanda L and Booth, Clarissa D and Albert, Karlee and Hunyara, John L and Rechtzigel, Mitchell J and Duelli, Fox J and Leppert, Hannah G and Rigo, Frank and Smit, Trisha and Jafar-Nejad, Paymaan and Weimer, Jill M and Drack, Arlene V and Hastings, Michelle L},
  title = {Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease},
  journal = {Nucleic Acids Research},
  year = {2025},
  doi = {10.1093/nar/gkaf1141}
}
Kostenlos starten →